Table 2.
Summary of selected characteristics of the 39 963 patients in the cohort with at least one encounter between 1 April 2021 and 31 October 2022
| Age, mean (SD) years | 73.00 (13.56) |
| Race and ethnicity, n (%) | |
| Non-Hispanic White | 25 894 (64.8%) |
| Non-Hispanic Black | 5115 (12.8%) |
| Non-Hispanic Asian | 1693 (4.2%) |
| Non-Hispanic Pacific Islander/Native Hawaiian/American Indian | 69 (0.2%) |
| Non-Hispanic others | 12 (0.0%) |
| Non-Hispanic multiracial | 143 (0.4%) |
| Hispanic | 4089 (10.2%) |
| Refused/unknown | 2620 (6.6%) |
| Missing | 328 (0.8%) |
| Language, n (%) | |
| English | 33 680 (84.3%) |
| Spanish | 1826 (4.6%) |
| Russian | 2169 (5.4%) |
| Chinese | 365 (0.9%) |
| Bengali | 124 (0.3%) |
| Smoking status, n (%) | |
| Current | 2281 (5.7%) |
| Former | 17 108 (42.8%) |
| Never | 20 435 (51.1%) |
| Unknown | 88 (0.2%) |
| Missing | 51 (0.1%) |
| Insurance, n (%) | |
| Medicare | 29 707 (74.3%) |
| Medicaid | 2940 (7.4%) |
| Commercial | 7152 (17.9%) |
| Other | 54 (0.1%) |
| Missing | 110 (0.3%) |
| Sex, n (%) | |
| Male | 22 228 (55.6%) |
| Female | 17 733 (44.4%) |
| Unknown | 2 (0.0%) |
| 10 common comorbidities, n (%) | |
| Hypertension, uncomplicated | 30 621 (76.8%) |
| Cardiac arrhythmias | 22 496 (56.4%) |
| Obesity | 13 105 (32.9%) |
| Valvular disease | 13 303 (33.4%) |
| Peripheral vascular disorders | 12 868 (32.3%) |
| Diabetes, uncomplicated | 12 041 (30.2%) |
| Renal failure | 10 389 (26.0%) |
| Fluid and electrolyte disorders | 10 162 (25.5%) |
| Chronic pulmonary disease | 10 030 (25.1%) |
| Diabetes, complicated | 8968 (22.5%) |
| Heart failure medication prescription, n (%) | |
| Betablocker | 33 606 (84.3%) |
| ACEi/ARB/ARNI | 32 626 (81.8%) |
| MRA | 11 611 (29.1%) |
| SGLT2i | 7472 (18.7%) |
| Number of heart failure medication prescription by person, mean (SD) | 2.13 (0.89) |
| Community type, n (%) | |
| Urban metropolitan area | 39 567 (99.0%) |
| Suburban area | 315 (0.8%) |
| Rural area | 80 (0.2%) |
ARB, angiotensin receptor blocker; ARNI, angiotensin receptor neprilysin inhibitor; MRA, mineralocorticoid receptor antagonist; SGLT2i, sodium-glucose cotransporter 2 inhibitor.